BioCentury
ARTICLE | Clinical News

CNDO-109 regulatory update

June 25, 2012 7:00 AM UTC

FDA granted Orphan Drug designation for Coronado's CNDO-109 to treat acute myelogenous leukemia (AML). Next half, the company plans to start a dose-escalation Phase I/II trial to evaluate the product ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article